Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (1): 94-98.doi: 10.12092/j.issn.1009-2501.2019.01.016

Previous Articles     Next Articles

Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification

CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua   

  1. Ningbo Drug Research Center,Ningbo 315010,Zhejiang, China
  • Received:2018-06-22 Revised:2018-11-23 Online:2019-01-26 Published:2019-01-25

Abstract:

AIM: To investigate the clinical efficacy and safety of low dose risperidone combined with trazodone in the treatment of anxiety disorders, depression disorders and insomnia from heroin addicts after detoxification. METHODS: One hundred and fifty patients were divided into 3 groups randomly. Fifty patients of risperidone combined with trazodone group(R+T group) were given low dose risperidone and trazodone.Fifty patients of the trazodone group(T group)were only given trazodone and 50 patients of the risperidone group(R group) were only given low dose risperidone, respectively. Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD) and Pittsburgh Sleep Quality Index (PSQI) were used to evaluate the efficacy before treatment and at the end of 2, 4, 6 weeks after treatment. The safety was evaluated with Treatment Emergent Side-effect Scale (TESS) and laboratory test. RESULTS:Twenty-one patients were fallen off after 6 weeks, and 129 patients completed the course of treatment. There was significantly decrease compared with HAMA,HAMD and PSQI scores in R+T group at the end of 2,4,6 weeks after treatment, the differences were statistically significant (P<0.05); the HAMA,HAMD and PSQI scores of R group were significantly decreased compared with before treatment at the end of 4,6 week, the differences were statistically significant (P<0.05); the HAMA, HAMD scores of T group were significantly decreased compared with before treatment , the differences were statistically significant (P<0.05).PSQI scores decreased significantly only at the end of 6 week, the differences were statistically significant (P<0.05). There were significant differences in HAMA,HAMD and PSQI scores of R+T group compared with group R and group T at the end of 2,4,6 week (P<0.05). Comparison of the TESS scores in the 3 group at the end of 4,6 weeks after treatment showed no significant differences (P>0.05). CONCLUSION:Low dose risperidone combined with trazodone can significantly improve heroin addicts during detoxification of anxiety, depression and sleep quality. The effect of combined application is better than single drug use.

Key words: heroin addicts, trazodone, risperidone, anxiety, depression, insomnia

CLC Number: